Non-fucosylated Anti-Human SLAMF7 (Elotuzumab) Therapeutic Antibody (CAT#: BioBet-025ZP) Datasheet

SLAMF7

SLAM family member 7

19A; CS1; CD319; CRACC

Membrane;Single-pass type I membrane protein

Diseases associated with SLAMF7 include Smoldering Myeloma and Submandibular Gland Disease.

Its related pathways are Innate Immune System and Class I MHC mediated antigen processing and presentation.

1.Self-ligand receptor of the signaling lymphocyte activation molecule (SLAM) family. The SLAM receptor triggered by the homo- or heterotypic cell-cell interaction regulates the activation and differentiation of various immune cells, and therefore participates in the regulation and interconnection of innate immune response and adaptive immune response. Activity is controlled by the presence or absence of small cytoplasmic adaptor proteins SH2D1A/SAP and/or SH2D1B/EAT-2. Isoform 1 mediates NK cell activation through an erk-mediated pathway that is independent of sh2d1 extracellular signal regulation (PubMed: 11698418). By relying on the phosphorylated SH2D1B mechanism, it positively regulates the function of NK cells. The downstream signals involve PLCG1, PLCG2 and PI3K (PubMed: 16339536). In addition to the interaction between heterotypic NK cells and target cells, homotypic interactions between NK cells may also contribute to activation. However, in the absence of SH2D1B, NK cell function will be inhibited. It also has an inhibitory effect on T cells (similar). May be involved in lymphocyte adhesion (PubMed: 11802771). Monocytes activated by lipopolysaccharide negatively regulate the production of pro-inflammatory cytokines (PubMed: 23695528). 2.Isoform 3 does not mediate the activation of any NK cells.

1.Glycosylation at Asn142, Asn148, Asn172, Asn176, Asn204, and Asn98 2.Modification sites at PhosphoSitePlus

Protein Based Therapies
Monoclonal antibody (mAb)

IgG1

Elotuzumab

Mouse

Human

Elotuzumab is a humanized monoclonal antibody for relapsed multiple myeloma. Elotuzumab is produced in NS0 cells by recombinant DNA technology and targets SLAMF7. On November 30, 2015, Elotuzumab was approved by the US Food and Drug Administration.

Refractory Multiple Myeloma

HuLuc63

Elotuzumab is a humanized IgG1 monoclonal antibody that specifically binds the SLAMF7 protein. SLAMF7 is a member of the signaling lymphocyte activation molecule family and is expressed on myeloma cells. Studies have shown that Elotuzumab directly activates natural killer cells through the SLAMF7 pathway and Fc receptors, further promotes interaction with Natural Killer cells through antibody-dependent cytotoxicity (ADCC), and mediates killing of myeloma cells.

Refractory Multiple Myeloma